Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CLL 2020 | CD8+ T cell expansion in CLL patients treated with ibrutinib

Maria Joao Baptista • 13 Nov 2020
ESH CLL 2020
Chronic Lymphocytic Leukemia Leukemia Antibodies Ibrutinib

Maria Joao Baptista, PharmD, PhD, Josep Carreras Leukaemia Research Institute, Barcelona, Spain, highlights the results of a study evaluating the T-cell repertoire in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Ibrutinib was found to induce a more oligoclonal T cell receptor (TCR) repertoire in patients with chronic lymphocytic leukemia (CLL), driven by expansion of specific CD8+ clonotypes. This study supports the investigation of therapeutic strategies combining ibrutinib with T- cell-directed immunotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals